D. Osborne

Direttore Finanziario/CFO presso Melt Pharmaceuticals, Inc.

45 anni

Health Technology

Posizioni attive di D. Osborne

Società	Posizione	Inizio	Fine
Melt Pharmaceuticals, Inc. Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.	Direttore Finanziario/CFO	01/02/2022	-

Società	Posizione	Inizio	Fine
PRECIGEN, INC.	Comptroller/Controller/Auditor	01/04/2016	10/06/2021
	Direttore Finanziario/CFO	-	10/06/2021
	Corporate Officer/Principal	01/07/2011	01/04/2016

Distribuzione geografica

Stati Uniti

Posizioni

Director of Finance/CFO	2
Comptroller/Controller/Auditor	1
Corporate Officer/Principal	1

Settori

Health Technology

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
PRECIGEN, INC.	Health Technology

Aziende private	1
Melt Pharmaceuticals, Inc. Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.	Health Technology

Aziende private

Health Technology